Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives.

Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives. Abstract Text:

BACKGROUND: Birch pollen and pollen from related trees of the Fagales order are a major cause of allergic rhinitis, conjunctivitis, and asthma through the spring season in northern and central Europe. OBJECTIVE: To investigate the clinical effects of injection immunotherapy with genetically modified derivatives of major birch pollen allergen Bet v 1 on pollen-induced allergic symptoms. METHODS: A three-arm double-blind placebo-controlled immunotherapy study was conducted with one pre-seasonal course of treatment using two derivatives of Bet v 1, namely a recombinant Bet v 1 trimer and an equimolar mixture of two recombinant Bet v 1 fragments together representing the whole protein sequence. Analysis of local and systemic adverse events was performed for 124 patients who had received at least one dose of medication. Clinical efficacy was monitored by symptom medication scores and interval scoring in the per protocol-treated population (n=84). In addition, skin and nasal provocation responses and allergen-specific antibodies were assessed. RESULTS: There were trends towards improvement in the subjects' well-being and clinical symptoms (nasal scores), although comparisons with a placebo group did not show statistical significance in the main end-point, the combined symptom medication score. Reductions in skin and nasal sensitivity were observed for some subjects with a trend for the Bet v 1 trimer to be more effective than the fragments. Treatment induced strong IgG1 and IgG4 allergen-specific antibody responses. Local injection-site reactions were most frequent in the trimer group affecting 59.5% of patients as opposed to 37.8% and 30.6% in the fragment and placebo groups, respectively. Systemic reactions were elicited more frequently by fragments. A large proportion of adverse side-effects appeared hours following injections, and might be attributable to concurrent exposure to related pollens. CONCLUSION: Single courses of injection immunotherapy with Bet v 1 allergen derivatives showed trends towards improved well-being and reduced reactivity to specific allergen provocation, but did not yield significant improvement in the combined symptom medication score in this study.

Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Clinical and experimental allergy : journal of the

VOLUME: 38

Page Numbers: 1514-25

Journal Abbreviation: Clin. Exp. Allergy

ISSN: 1365-2222

DAY: 28

MONTH: 06

YEAR: 2008

Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8906443

Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives.

AFFILIATION: Service de Pneumologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Clin Exp Allergy

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives Related Publications

• Antibacterial action of commercial nitromersol preparations.
• Calibrated leak balloon microcatheter: a device for arterial exploration and occlusive therapy.
• Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives.
• Clinical experience with recombinant pollen allergens.
• Condensation of hydroxy and methoxy N-methylbenzylamines with heterocyclic chlorides.
• Cytology of bronchial secretions; its role in the diagnosis of cancer.
• Development of a homogeneous high-throughput live-cell g-protein-coupled receptor binding assay.
• Diagnosis of cancer of the lung by the cytologic method.
• Effects of estrogen and prostaglandin on progesterone-delayed farrowing.
• Effects of sensorimotor adaptation training on functional mobility in older adults.
• MR imaging of corpus callosotomy.
• Methaqualone--a sedative or mild tranquilizer for geriatric patients.
• Monoclonal antibodies.
• Occupational therapist--observer or evaluator?
• Opening the queen's closet: Henrietta Maria, Elizabeth Cromwell, and the politics of cookery.
• Rathke's cleft cyst as a secondary cause of headache:a case report.
• Remote effects of neuroblastoma.
• The School Nurse as a Health Educator.
• The effect of increasing inertia upon vertical ground reaction forces and temporal kinematics during locomotion.
• The magnetic susceptibility of atomic iodine.
• The micro-estimation and origin of methylamine in Mercurialis perennis L.
• The micro-estimation and origin of trimethylamine in Chenopodium vulvaria L.
• The relations between cognition and the independent living skill of shopping in people with schizophrenia.
• Traumatic pericallosal artery aneurysm.